Ranbaxy's New Head Says Firm's Focus To Remain On Generics
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories became a powerhouse in the generics sector of the drug-making industry and intends to retain that position under Japanese control
|
India's Ranbaxy Laboratories became a powerhouse in the generics sector of the drug-making industry and intends to retain that position under Japanese control. Ranbaxy CEO and Managing Director Atul Sobti said in an interview his focus is to be sure the generics research business fits well with Daiichi Sankyo's traditional branded-drug business. Ranbaxy had extended its focus to innovative drugs and even has one for treating malaria in Phase III trials in India and Thailand. But Sobti said the priority would remain on generics, reflecting the recent decision to establish Daiichi Sankyo Espha to market them, primarily to the Japanese market. (Click here for more) "Ranbaxy To Focus More On Generic Drugs" - Livemint (India) (5/16/10) |